S&P Global names Thomas Kim chief legal officer effective Oct. 19, 2026
Bitget2026/10/09 11:30S&P Global named Thomas Kim chief legal officer effective Oct. 19, 2026, overseeing legal, government affairs, risk, compliance. Kim previously served as chief legal officer and corporate secretary at Gartner and Thomson Reuters. Outgoing chief legal officer Steve Kemps plans to retire at year-end, staying as special advisor through Dec. 31, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. S&P Global Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610090730PR_NEWS_USPR_____NY67751) on October 09, 2026, and is solely responsible for the information contained therein.
- S&P Global named Thomas Kim chief legal officer effective Oct. 19, 2026, overseeing legal, government affairs, risk, compliance.
- Kim previously served as chief legal officer and corporate secretary at Gartner and Thomson Reuters.
- Outgoing chief legal officer Steve Kemps plans to retire at year-end, staying as special advisor through Dec. 31, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized
BlackRock has turned bullish on U.S. Treasury bonds for the first time in six years, upgrading short-term bonds to overweight and downgrading U.S. equities to neutral, stating that rate hike expectations are excessive and it is time to lock in yields.

AstraZeneca (AZN.US) Relizumab's new indication is expected to be included in priority review
Relizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billions USD in 2025 (YOY +20.23%).
4 Big Bank Earnings to Watch This Week as Wall Street Turns Bullish
Mortgage rates return to 7%, pending home sales in the US fall to nearly a twelve-year low
According to Freddie Mac data, the 30-year fixed mortgage rate has risen to 7.4%, the highest level in nearly three years. Data from real estate brokerage Redfin shows that the volume of existing home pending sales in September fell 4% month-on-month, marking the largest single-month drop in over three years and hitting the lowest level since 2014. Nearly one-fifth of sellers have reduced prices, and the home purchase contract cancellation rate has reached a record high of 14.5%. Inventory levels have risen to the highest since March 2020, but high financing costs continue to constrain transactions.
